Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hospices Civils de Lyon
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with metastatic melanoma with an activating BRAF mutation
Who received at least one line of immunotherapy
Whose disease is resistant to a BRAF inhibitor used as a single agent or in combination with a MEK inhibitor
Who received either cytotoxic chemotherapy or the combination dabrafenib + trametinib + hydroxychloroquine after disease progression to dabrafenib/trametinib from January 2008 to June 2020 in the Dermatology ward of the Lyon Sud Hospital
You may not be if
Patients who did not received an immunotherapy prior to dabrafenib/trametinib treatment
